ABSTRACT:
In this article, we will discuss about the molecular basis of sickle cell anemia. It is a disease in which shape of the red blood cells due to a mutation in which valine replace the glutamic acid. We will discuss the several genetic and epigenetic factors that cause the disease. It is hereditary blood genetic disorder, that is due to mutation in beta chain of hemoglobin. It causes the polymerization of HBs polymer. We will also discuss the solutions to prevent and cure sickle cell anemia.
INTRODUCTION OF MOLECULAR BASIS OF SICKLE CELL ANEMIA:
Sickle cell anemia is a hereditary blood disorder characterized by the abnormal shape of red blood cells. This condition affects millions of people worldwide, particularly those of African, Mediterranean, and Middle Eastern descent. Understanding the molecular basis of sickle cell anemia is crucial for developing effective treatments and improving the quality of life for affected individuals. In this article, we will explore the underlying genetic mutation responsible for sickle cell anemia and its impact on the structure and function of red blood cells. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432324
THE GENETIC MUTATION-MOLECULAR BASIS OF SICKLE CELL ANEMIA:
Sickle cell anemia is caused by a single point mutation in the gene encoding the beta-globin subunit of hemoglobin, the protein responsible for oxygen transport in red blood cells. This mutation results in the substitution of a single amino acid, glutamic acid, with valine at position 6 of the beta-globin chain. This genetic alteration leads to the production of abnormal hemoglobin known as hemoglobin S (HbS).
STRUCTURAL CHANGES IN RED BLOOD CELLS:
The presence of HbS causes red blood cells to become rigid and assume a sickle-like shape when deoxygenated. This abnormal shape hinders their ability to flow smoothly through blood vessels, leading to blockages and reduced oxygen delivery to tissues and organs. The sickling of red blood cells is a hallmark feature of sickle cell anemia and is responsible for many of the disease’s clinical manifestations.
MOLECULAR BASIS OR MECHANISM OF SICKLE CELL ANEMIA:
The molecular basis of sickle cell anemia lies in the polymerization of deoxygenated HbS molecules. Under low oxygen conditions, HbS molecules tend to aggregate and form long, insoluble fibers within the red blood cells. These fibers distort the cell’s shape, leading to the characteristic sickling phenotype. The polymerization process is influenced by various factors, including the concentration of HbS, the presence of other hemoglobin variants, and the overall oxygen tension.
CONSEQUENCES AND CLINICAL MANIFESTATIONS:
The sickling of red blood cells in sickle cell anemia leads to a range of clinical manifestations. These include chronic anemia, vaso-occlusive crises, increased susceptibility to infections, and organ damage. The blockage of blood vessels by sickled cells can cause severe pain, tissue damage, and organ dysfunction. Additionally, the shortened lifespan of sickled red blood cells contributes to chronic anemia, leading to fatigue, shortness of breath, and reduced physical endurance.
CONCLUSION:
Understanding the molecular basis of sickle cell anemia has provided valuable insights into the pathophysiology of the disease. The single amino acid substitution in the beta-globin gene leads to the production of abnormal hemoglobin, resulting in the sickling of red blood cells. This molecular defect underlies the clinical manifestations of sickle cell anemia. Advances in molecular biology and genetics have paved the way for targeted therapies, such as gene editing and gene therapy, offering hope for a cure or improved treatments for this debilitating condition.
REFERENCES:
Steinberg MH. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. ScientificWorldJournal. 2008;8:1295-1324. doi: 10.1100/tsw.2008.169 https://pubmed.ncbi.nlm.nih.gov/19112541
Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017;127(3):750-760. doi: 10.1172/JCI89741
Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11):762-769. doi: 10.1056/NEJM199709113371107
Aidoo, M., et al. Protective effects of the sickle-cell gene against malaria morbidity and mortality. Lancet 359, 1311–1312 (2002)
Charache, S., et al. Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia. New England Journal of Medicine 332, 1317–1322 (1995)
Herrick, J. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Archives of Internal Medicine 6, 517–521 (1910)
